| This week's sponsor is Pfizer. | | | |
Top Stories Friday, December 2, 2016 After getting off its $100 million-plus IPO in the summer, gene editing biotech Intellia Therapeutics is getting ready for human tests of its preclinical CRISPR tech with new digs designed to help bolster its research capabilities. Friday, December 2, 2016 Boehringer Ingelheim is slashing its head count by around 244, with the bulk of the cutbacks affecting its small-molecule discovery operations in Ridgefield, Connecticut. Friday, December 2, 2016 Amryt Pharma has secured a €20 million loan from the European Investment Bank (EIB) to fund a pivotal trial of its lead candidate in epidermolysis bullosa. The specialty pharma, which is chaired by Shire founder Harry Stratford, is set to start the phase 3 clinical trial early next year. Thursday, December 1, 2016 Caltech researchers have shown in mouse models that gut bacteria can encourage the progression of some Parkinson’s disease hallmarks. These bacteria could serve as biomarkers or therapeutic targets for the neurodegenerative disorder. Thursday, December 1, 2016 In this week's EuroBiotech Report, Kymab raised $100 million, AstraZeneca and Bicycle penned a pact, Heptares is set to buy a G7 and more. Thursday, December 1, 2016 In this week's FiercePharmaAsia wrap-up, GSK China has a new leader, Japan's Opdivo price cut raises concerns in the country's regulatory environment, Takeda is building a €100M vaccine site in Germany, and more. Friday, December 2, 2016 Pfizer’s longtime official Maddaluna is retiring as EVP, Thomas Willemsen will lead GSK China, Taro taps Sun Pharma CFO as new CEO. Plus more hirings, firings and retirings throughout the industry. | | | Amgen and Allergan have asked the EMA to look at its Avastin copycat ABP 215. Release After posting some impressive data for its new CAR-T med this week, Bluebird Bio has made two new senior appointments. Statement Boston Scientific has secured a $75 million buyout of Neovasc's advanced biological tissue capabilities. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA DeviceTalks December 12, 2016 | Newport Beach, CA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd | 